Tesamorelin is a synthetic analogue of Growth Hormone-Releasing Hormone (GHRH). It mimics the action of GHRH and signals the pituitary gland to release growth hormone.
Tesamorelin is not indicated as a general weight-loss treatment. It has been studied and approved for reducing excess visceral abdominal fat in adults with HIV-associated lipodystrophy.
What Is GHRH?
Growth Hormone-Releasing Hormone (GHRH) is a natural peptide produced in the hypothalamus of the brain. It has following functions:
- GH Secretion: activates the pituitary gland to release growth hormone.
- Metabolism: influence process related to protein synthesis and fat breakdown.
- Cell Repair: helps in recovery and growth of tissue.
- Daily Rhythm: contributes to the normal pattern of growth hormone secretion.
Natural GHRH is broken down relatively quickly in the body. Tesamorelin was developed as a longer-acting GHRH analogue.
Tesmorelin At A Glance
| Features | Details |
|---|---|
| Primary target | Excess visceral abdominal fat |
| How it works | Stimulates release of GH and IGF-1 |
| Clinical indication | HIV associated Lipodystrophy |
| Main clinical effect | Reduces visceral abdominal fat |
Key Research & Clinical Findings
- Secretion of Natural Growth Hormone
- Targeted Visceral Fat Loss
- Favorable Glucose Profile
- Hepatic fat and metabolic health
- Lean body mass and body composition
Bottom Line
Tesamorelin has been studied for its effects on visceral abdominal fat and related metabolic measures. Research has examined its effects on visceral fat, body composition, liver fat, and lean mass. Unlike medicines used specifically for appetite-based weight management, tesamorelin is indicated for reducing excess visceral abdominal fat in adults with HIV-associated lipodystrophy.
Disclaimer: This information is provided only for educational and scientific purposes. Tesamorelin is an FDA-approved prescription drug for a specific medical indication in adults with HIV-associated lipodystrophy and is not indicated for general weight-loss management. This article does not provide medical advice or recommend the use of tesamorelin for weight loss or any other condition.
References
- Falutz, J., Allas, S., Blot, K., Potvin, D., Kotler, D., Somero, M., Berger, D., Brown, S., Richmond, G., Fessel, J., Turner, R., & Grinspoon, S. (2007). Metabolic effects of a growth hormone–releasing factor in patients with HIV. New England Journal of Medicine, 357(23), 2359–2370. https://doi.org/10.1056/NEJMoa072375
- tanley, T. L., Feldpausch, M. N., Oh, J., Branch, K. L., Lee, H., Torriani, M., & Grinspoon, S. K. (2014). Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: A randomized clinical trial. JAMA, 312(4), 380–389. https://doi.org/10.1001/jama.2014.8334
